Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vepoloxamer - Savara Pharmaceuticals

Next Previous
X
Search
Drug Profile

Vepoloxamer - Savara Pharmaceuticals

Alternative Names: ANX-188; CRL-5861; FLOCOR; MST-188; Poloxamer 188 NF; Purified 188; Purified poloxamer 188

Latest Information Update: 29 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytRx Corporation
  • Developer Mast Therapeutics; Savara Pharmaceuticals
  • Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
  • Mechanism of Action Cell membrane structure modulators; Surface active agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders; Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute lung injury; Cancer; CNS disorders; Muscular dystrophies; Myocardial infarction; Peripheral nervous system diseases; Stroke
  • Discontinued Chronic heart failure; Peripheral arterial occlusive disorders; Vaso-occlusive crisis

Most Recent Events

  • 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
  • 09 Apr 2021 No development reported - Phase-II for Myocardial infarction (IV)
  • 28 Mar 2019 No recent reports of development identified for preclinical development in Stroke in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top